http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Scholar Rock to Participate in Upcoming Investor Conferences
-
Scholar Rock to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023
-
Scholar Rock to Present Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 38th Annual Meeting
-
Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business Progress
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
New 36-Month Apitegromab Extension Data Reinforce Long-Term Substantial and Sustained Improvement of Motor Function in Phase 2 TOPAZ Trial Patients with Nonambulatory Spinal Muscular Atrophy
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock to Present at the Jefferies Healthcare Conference
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Reports First Quarter 2023 Financial Results and Highlights Business Progress
-
Scholar Rock to Present New Data Evaluating Apitegromab at 36 Months from the Phase 2 TOPAZ trial at the 2023 Annual Cure SMA Conference
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Holding (SRRK) Announces the Addition of Richard Brudnick to Its Board of Directors
-
Scholar Rock Announces the Addition of Richard Brudnick to Its Board of Directors
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress
-
Scholar Rock to Present 24-Month Data from the Phase 2 TOPAZ trial at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
-
Scholar Rock to Present at the Cowen 43rd Annual Health Care Conference
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer
-
Scholar Rock Holding Corp. (SRRK) Provides Corporate Update and Highlights Priorities for 2023
-
Scholar Rock Provides Corporate Update and Highlights Priorities for 2023
-
Scholar Rock to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress
-
Scholar Rock Holding Corp. (SRRK) Says Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy
-
Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy
-
Scholar Rock Holding (SRRK) Appoints Jing L. Marantz as Chief Medical Officer
-
Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer
-
Scholar Rock to Participate in Upcoming Investor Conferences
-
Scholar Rock (SRRK) Reports Strong New 24-month Data from Phase 2 TOPAZ Data
-
New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA
-
Scholar Rock to Present Data from the Phase 1 DRAGON trial at the SITC 37th Annual Meeting
-
Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy
-
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Holding Corp. (SRRK) Appoints Jay Backstrom as CEO
-
Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer
-
Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit
-
Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress
-
Scholar Rock (SRRK) Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors
-
Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors
-
Scholar Rock to Participate in the 2022 Wedbush PacGrow Healthcare Conference
-
Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFβ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference
-
Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)
-
Scholar Rock Holding Corp. (SRRK) Reports Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months
-
Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular At
-
Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference
